Moving forward with dolutegravir in children weighing less than 20 kg

Affiliations

¹ Department of Paediatrics and Child Health, Stellenbosch University and Tygerberg Hospital, Faculty of medicine and Health Sciences, Parrow, Cape Town, 7505, South Africa. Electronic address: hrabie@sun.ac.za.
² Department of Paediatrics and Child Health, Stellenbosch University and Tygerberg Hospital, Faculty of medicine and Health Sciences, Parrow, Cape Town, 7505, South Africa.

Comment

Helena Rabie et al. Lancet HIV. 2022 May.

. 2022 May;9(5):e301-e302.

doi: 10.1016/S2352-3018(22)00062-5.

¹ Department of Paediatrics and Child Health, Stellenbosch University and Tygerberg Hospital, Faculty of medicine and Health Sciences, Parrow, Cape Town, 7505, South Africa. Electronic address: hrabie@sun.ac.za.
² Department of Paediatrics and Child Health, Stellenbosch University and Tygerberg Hospital, Faculty of medicine and Health Sciences, Parrow, Cape Town, 7505, South Africa.

No abstract available

Conflict of interest statement

HR reports teaching and conference fees from AbbVie. JL and LJF declare no competing interests.

Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial.
Ruel TD, Acosta EP, Liu JP, Gray KP, George K, Montañez N, Popson S, Buchanan AM, Bartlett M, Dayton D, Anthony P, Brothers C, Vavro C, Singh R, Koech L, Vhembo T, Mmbaga BT, Pinto JA, Dobbels EFM, Archary M, Chokephaibulkit K, Ounchanum P, Deville JG, Hazra R, Townley E, Wiznia A; IMPAACT P1093 team. Ruel TD, et al. Lancet HIV. 2022 May;9(5):e332-e340. doi: 10.1016/S2352-3018(22)00044-3. Lancet HIV. 2022. PMID: 35489377 Free PMC article. Clinical Trial.